ArticleCureus2024
Superior Nasal Septal Deviation as a Contributing Factor for Dacryocystitis.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Dacryocystitis (DC) is a disease most often caused by an obstruction of the nasolacrimal duct, leading to over-accumulation of tears in the lacrimal sac, epiphora, and aseptic inflammation. External and endoscopic dacryocystorhinostomy (DCR) aims to restore the tear pathway by creating a bypass from the lacrimal sac to the nose. The aim of this study is to investigate superior nasal septal deviation as a possible contributing factor in the incidence and treatment of dacryocystitis. Methods This retrospective study included 36 patients surgically treated for chronic dacryocystitis from September 2019 to September 2024. Results Twenty-eight out of the 36 studied patients (77.8%) were females. The average age of all patients was 66.8 years, with 69.4% being in the 50-70 years age group while 30.6% being older than 70 years. Superior nasal septal deviation was present in all patients, with 18 (50%) cases being towards the side of the DC and 11 (30.6%) away from the side of the DC. In seven cases (19.4%), the septum was S-shaped. In none of the cases in which the endoscopic approach was used was a septoplasty necessary. Concha bullosa was observed in five cases (13.9%) and was treated in all. A total of 32 patients were treated endoscopically (88.9%) and four (11.1%) by the Toti external approach method. The intraoperative microbiologic culture was positive in a total of nine cases (25%), five being coagulase-negative Staphylococci (13.9%), two being S. pneumoniae (2.8%), and one each of S. aureus (2.8%) and Pseudomonas maltophilia (5.6%). A re-stenosis was observed in five patients (13.9%). Conclusion Superior nasal septal deviation is an emerging factor both for the incidence of dacryocystitis and the development of re-stenosis after dacryocystorhinostomy. Further studies are needed to find the exact types of nasal septum deviations carrying the greatest risk for disease development, as well as the role of septoplasty in the result of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.